Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SLAM DRILLS MORE COPPER MINERALIZATION AT GOODWIN (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News AstraZeneca ADR Representing 0.5 Ord Shs AZN

Consumer Cyclical Healthcare Advertising Agencies
AstraZeneca PLC is a science-led biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza... see more

Recent & Breaking News (NDAQ:AZN)

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds AstraZeneca (AZN) Investors of Pending Securities Class Action, Encourages Investors Who Suffered Losses to Contact the Firm

ACCESSWIRE IA February 19, 2021

AZN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of March 29, 2021 in the Class Action Filed on Behalf of Astrazeneca Plc Limited Shareholders

Newsfile February 19, 2021

AZN DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against AstraZeneca PLC- AZN

GlobeNewswire February 19, 2021

DEADLINE ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AstraZeneca PLC and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

ACCESSWIRE IA February 19, 2021

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts AstraZeneca (AZN) Investors of Securities Fraud Case Related to Potential COVID-19 Treatment Filed, Filing Deadline Approaching

Newsfile February 18, 2021

AstraZeneca Shareholder Notice

Newsfile February 18, 2021

Breaking News: Rosen, Globally Respected Investor Counsel, Encourages AstraZeneca PLC Investors with Large Losses to Secure Counsel Before Important Deadline - AZN

Newsfile February 18, 2021

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds AstraZeneca (AZN) Investors of Securities Class Action Lead Plaintiff Deadline

ACCESSWIRE IA February 17, 2021

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against AstraZeneca, iRhythm Technologies, Tyson Foods, and Clover Health Investments and Encourages Investors to Contact the Firm

GlobeNewswire February 17, 2021

AstraZeneca Shareholder Alert

Newsfile February 17, 2021

BREAKING NEWS: ROSEN, LEADING INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors with Large Losses to Secure Counsel Before Important Deadline - AZN

GlobeNewswire February 17, 2021

AZN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of March 29, 2021 in the Class Action Filed on Behalf of Astrazeneca Plc Limited Shareholders

Newsfile February 17, 2021

BTBT, VYGR & AZN Class Actions: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders of Class Actions and Encourages Investors to Contact the Firm

GlobeNewswire February 17, 2021

IDMC has Concluded that OlympiA Trial of LYNPARZA® (olaparib) Crossed Superiority Boundary for Invasive Disease-free Survival Vs. Placebo at Planned Interim Analysis

Business Wire February 17, 2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Astrazeneca Plc of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 29, 2021 - AZN

Newsfile February 16, 2021

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds AstraZeneca (AZN) Investors of Securities Fraud Case Related to Potential COVID-19 Treatment Filed

GlobeNewswire February 16, 2021

AstraZeneca Deadline Alert

Newsfile February 16, 2021

/C O R R E C T I O N -- AliveCor/

PR Newswire February 16, 2021

AliveCor Announces Collaboration with AstraZeneca to Develop Non-Invasive Potassium Monitoring Solutions

PR Newswire February 16, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AstraZeneca plc of Class Action Lawsuit and Upcoming Deadline - AZN

Newsfile February 15, 2021